West Pharmaceutical (WST) Reports Q4 Earnings: What Key Metrics Have to Say
For the quarter ended December 2023, West Pharmaceutical Services (WST) reported revenue of $732 million, up 3.3% over the same period last year. EPS came in at $1.83, compared to $1.77 in the year-ago quarter.
The reported revenue represents a surprise of -0.93% over the Zacks Consensus Estimate of $738.9 million. With the consensus EPS estimate being $1.78, the EPS surprise was +2.81%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how West Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Change in Organic Revenue: 1.4% versus 2.9% estimated by two analysts on average.
Net Sales- Contract-Manufactured Products: $138.30 million versus the two-analyst average estimate of $132.82 million. The reported number represents a year-over-year change of +11.6%.
Net Sales- Proprietary Products: $593.70 million compared to the $604.89 million average estimate based on two analysts. The reported number represents a change of +1.5% year over year.
Gross Profit- Proprietary Products: $253.40 million compared to the $249.13 million average estimate based on two analysts.
Gross Profit- Contract-Manufactured Products: $24.70 million versus $22.26 million estimated by two analysts on average.
View all Key Company Metrics for West Pharmaceutical here>>>
Shares of West Pharmaceutical have returned +20.2% over the past month versus the Zacks S&P 500 composite's +4.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report
